Old wine in a new bottle: Ready to drink?

Abstract

In this issue of Blood, Walter et al describe the impact of minimal residual disease (MRD) as measured by multicolor flow cytometry (MCF) on relapse, progression-free survival (PFS), and overall survival (OS) in acute myeloid leukemia (AML) patients who received an allogeneic hematopoietic stem cell transplantation (alloHSCT).